Company intelligence / Profile preview

Advantage Silver Dental Arrest, LLC

Salem, Oregon, United States

Ownership: Private
Employees: ~1
Development stage: Other

Overview

The company's main product, Advantage Arrest Silver Diamine Fluoride 38%, received FDA clearance in 2014 as a medical device for treating dentinal hypersensitivity. In 2016, it became the first oral care product to receive the FDA's Breakthrough Therapy Designation for arresting tooth decay. Multiple clinical trials have shown efficacy in arresting dental caries. The NIH provided $9.8 million in 2017 to fund a Phase III randomized clinical trial using Advantage Arrest for arresting caries in children.

Therapeutic areas: OtherInfectious Diseases
Modalities: Silver diamine fluorideFluoride varnishPovidone-iodine
Industry: Therapeutic Medical Devices

Partnerships

Elevate Oral Care, LLC (exclusive distributor)

Beyond the preview

Go deeper on Advantage Silver Dental Arrest, LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Advantage Silver Dental Arrest, LLC.